Inicio › Leucemia mielógena aguda › Massachusetts
Ensayos clínicos de Leucemia mielógena aguda en Massachusetts
44 estudios sobre Leucemia mielógena aguda buscan participantes en Massachusetts.
Ciudades en Massachusetts
Texto oficial del estudio (inglés)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- MGH, Boston
- University of Massachusetts, Worcester
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 59 · Todos los sexos · Actualizado el 9 nov 2026 · NCT05554406A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06852222Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT05564390Study of REM-422 in Patients With AML or Higher Risk MDS
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06297941Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Lahey Clinic, Burlington
- y 1 más
ReclutandoFase 2
Edades de 18 a 59 · Todos los sexos · Actualizado el 28 oct 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06672146CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
ReclutandoFase 2Se aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 23 oct 2026 · NCT06059391A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07020533Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT06533761Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07355335A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT04256317Ziftomenib Maintenance Post Allo-HCT
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06440135Ivosidenib as Post-HSCT Maintenance for AML
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06707493A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Dana-Farber Cancer Center, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
ReclutandoFase 3
6 Months – 21 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT04293562(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT03471260Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 a 90 · Todos los sexos · Actualizado el 26 ago 2026 · NCT07439211The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 ago 2026 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 6 jul 2026 · NCT01351545A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT04024761SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT03113643Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT06138587Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- y 2 más
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 may 2026 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Todas las edades · Todos los sexos · Actualizado el 5 may 2026 · NCT07374029BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 1 abr 2026 · NCT06660368Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 mar 2026 · NCT06313437A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 66 · Todos los sexos · Actualizado el 17 mar 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 16 mar 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- DFCI, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 feb 2026 · NCT06950034De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.